Clinical trials: Eczema/Atopic Dermatitis, open to volunteers
Cutaneous T-cell Lymphoma, Sezary Syndrome
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
This is a tissue, urine, and blood banking protocol for cutaneous t-cell lymphoma (CTCL), eczema, and atopic dermatitis patients for current and future research.
- Conditions
- Cutaneous T-cell Lymphoma, Sezary Syndrome, Mycosis Fungoides, Eczema
- Trial name
- NCT00177268
- Testing
- Blood draw, skin biopsy or urine collection
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of Pittsburgh
Eczema, Dermatitis
Effects of Treatments on Atopic Dermatitis
Background: Atopic dermatitis, or eczema, is a chronic skin disorder. Patients sometimes have infections with S. aureus bacteria.
- Conditions
- Eczema, Dermatitis, Skin Diseases, Genetic, Dermatitis, Atopic
- Trial name
- NCT01631617
- Testing
- Trimethoprim/sulfamethoxazole (TMP/SMZ), Cephalexin, Doxycycline
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Healthy Volunteer, Atopic Dermatitis
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
This study will test an experimental study medicine called REGN20423 to see how effective it is in healthy participants (in Part A) and participants with atopic dermatitis (eczema) (in Part B).
- Trial name
- AURA-AD (NCT07527923)
- Testing
- REGN20423
- Where
- 9 sites in United States, Belgium
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema
The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body in adults and adolescents with moderate to severe atopic dermatitis (eczema).
- Trial name
- Tilrek (NCT07783425)
- Testing
- Tilrekimig, Dupilumab
- Where
- 50 sites in United States, Canada and 2 more
- Volunteers
- 1,375 people
- Sponsor
- Pfizer
Atopic Dermatitis, Atopic Dermatitis (AD)
Roflumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis
This Phase 3 study is designed to evaluate the efficacy and safety of once-daily roflumilast cream 0.3% in children, adolescents, and adults with moderate to severe atopic dermatitis.
- Conditions
- Atopic Dermatitis, Atopic Dermatitis (AD), Atopic Dermatitis (Eczema)
- Trial name
- INTEGUMENT 3 (NCT07916480)
- Testing
- Roflumilast Cream 0.3%, Vehicle Cream
- Where
- 4 sites in United States
- Volunteers
- 415 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Eczema, Atopic Dermatitis
Studies of Skin Microbes in Healthy People and in People With Skin Conditions
This study will examine microbes (e.g., bacteria, fungi, viruses) that live on human skin and how microbes contribute to health and disease.
- Trial name
- NCT00605878
- Where
- United States
- Volunteers
- 530 people, healthy volunteers welcome
- Sponsor
- National Human Genome Research Institute (NHGRI)
Atopic Dermatitis
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
This 24-month study will assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children 2 years of age or older with moderate-to-severe atopic dermatitis.
- Trial name
- NCT06807281
- Testing
- Abrocitinib
- Where
- 40 sites in United States, China and 5 more
- Volunteers
- 450 people
- Sponsor
- Pfizer
Atopic Dermatitis, Eczema, Atopic
A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
The purpose of this study is to learn if the study medicine (PF-08049820) is safe and effective for the treatment of atopic dermatitis (AD), also known as eczema, or atopic eczema.
- Trial name
- NCT07216027
- Testing
- PF-08049820
- Where
- 52 sites in United States, Bulgaria and 7 more
- Volunteers
- 165 people
- Sponsor
- Pfizer
Atopic Dermatitis, Eczema
Cardamom and Topical Roseomonas in Atopic Dermatitis
Background: Atopic dermatitis (AD), also called eczema, is a chronic skin condition. AD can make skin dry and itchy, and sometimes it can lead to serious health problems, such as asthma, food allergies, eye infections, and sleep…
- Trial name
- NCT06096857
- Testing
- Roseomonas mucosa (RSM2015) and Cardamom seeds
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Atopic Dermatitis
ADBest TREAT Registry
Atopic dermatitis is a chronic inflammatory skin disease associated with intense pruritus, recurrent eczematous lesions, sleep disturbance, and reduced quality of life.
- Trial name
- ADBest-TREAT (NCT07904546)
- Testing
- Abrocitinib, Baricitinib, Upadacitinib
- Where
- Germany
- Volunteers
- 5,000 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Acne, Atopic Dermatitis
Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers
The purpose of the study is to collect different samples for molecular characterization of inflammatory skin diseases.
- Conditions
- Acne, Atopic Dermatitis, Chronic Hand Eczema, Hidradenitis Suppurativa
- Trial name
- NCT05994976
- Testing
- Blood samples collection, Oral samples collection, Hair samples collection
- Where
- Canada
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Innovaderm Research Inc.
Atopic Dermatitis, Eczema
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to <18 years of age with moderate-to-severe atopic dermatitis.
- Trial name
- ADorable-2 (NCT05735483)
- Testing
- Lebrikizumab
- Where
- 94 sites in United States, Argentina and 11 more
- Volunteers
- 338 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis (AD), Eczema
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
This is a first-in-human, Phase 1, double-blind, randomized, placebo-controlled, dose-escalation study evaluating ARQ-234. The study is designed to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD)…
- Trial name
- NCT07453602
- Testing
- ARQ-234
- Where
- 7 sites in United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Arcutis Biotherapeutics, Inc.
Atopic Dermatitis, Eczema
Digital Mindfulness Meditation in Adolescents With Atopic Dermatitis
Atopic dermatitis is well reported to have a significant impact on well-being in adolescents with atopic dermatitis, without clear recommendations for intervention.
- Trial name
- MIND-AD (NCT07746427)
- Testing
- Digital App Mindfulness Meditation, Mindfulness Meditation Sheet
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Weill Medical College of Cornell University
Atopic Dermatitis
Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
This study will collect skin measurements from people with atopic dermatitis (AD) using the investigational Nevisense Go device.
- Trial name
- Detect-AD (NCT07645820)
- Testing
- Nevisense electrical impedance spectroscopy
- Where
- 13 sites in United States
- Volunteers
- 450 people
- Sponsor
- Castle Biosciences Incorporated
Atopic Dermatitis
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema
The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body when used together with medicated creams or ointments in adults and adolescents with moderate to severe atopic…
- Trial name
- NCT07765888
- Testing
- Tilrekimig
- Where
- 21 sites in United States, Japan
- Volunteers
- 375 people
- Sponsor
- Pfizer
Atopic Dermatitis
Retention of Vernix Caseosa in Newborns for Primary Prevention of Atopic Dermatitis
Atopic dermatitis (AD), also known as eczema, is a common chronic inflammatory skin disease that usually begins in infancy and causes significant itching, discomfort, and sleep disturbance.
- Trial name
- PROTEGO (NCT07333378)
- Testing
- Retention of Vernix Caseosa After Birth, Removal of Vernix Caseosa After Birth
- Where
- 2 sites in Chile
- Volunteers
- 1,383 people, healthy volunteers welcome
- Sponsor
- Pontificia Universidad Catolica de Chile
Atopic Dermatitis
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT06947993
- Testing
- GHZ339
- Where
- 105 sites in United States, Argentina and 15 more
- Volunteers
- 224 people
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis
Abrocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Years of Age
This clinical study is designed to test how well a medicine called abrocitinib works and how safe it is for young children (ages 2 to under 6) who have moderate-to-severe eczema (also known as atopic dermatitis).Eczema is a skin…
- Trial name
- NCT07823595
- Testing
- Abrocitinib
- Volunteers
- 90 people
- Sponsor
- Pfizer
Eczema, Atopic Dermatitis
The Impact of Dietary Salt on the Severity of Eczema
The goal of this clinical trial is to evaluate the feasibility of low-sodium diet to improve eczema severity. The main questions it aims to answer are: Does a low-sodium diet improve eczema severity? How does a low-sodium diet…
- Trial name
- iDOSE (NCT07447063)
- Testing
- Sodium chloride tablets
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco